Pharmacodynamic comparison of gefitinib plus carboplatin versus gemcitabine plus carboplatin in the treatment of advanced non-small-cell lung carcinoma

Gennian Mao, Shiyun Zhang, Hui

Abstract

The aim of this study was to explore the clinical efficacy and safety of two different dosage regimens, gefitinib plus carboplatin versus gemcitabine plus carboplatin in the treatment of advanced non-small-cell lung carcinoma (NSCLC). The control group received gemcitabine plus carboplatin treatment while the experimental group received gefitinib plus carboplatin. The result demonstrated that gefitinib plus carboplatin in the treatment of patients with advanced NSCLC was effective and safe, while further clinical investigation should be warranted.